Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
887 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02605863 | Enzalutamide for Bladder Cancer Chemoprevention | terminated | Phase 2 | 1 | University of RochesterOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00089102 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer | terminated | Phase 2 | 9 | Medical University of South CarolinaOTHER | 1 | Jul 16, 2018 | clinicaltrials |
| NCT00089128 |
| Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer |
| terminated |
| Phase 2 |
| 16 |
| Medical University of South CarolinaOTHER |
| 1 |
| Jul 12, 2018 |
| clinicaltrials |
| NCT00090870 | PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer | terminated | Phase 2 | 10 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00268450 | Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | terminated | Phase 2 | 21 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01482949 | A Rollover Protocol for Subjects Previously Treated With AGS-003 | terminated | Phase 2 | 2 | Argos TherapeuticsINDUSTRY | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02626754 | A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population | terminated | Phase 2 | 13 | vghtpe userOTHER_GOV | 1 | Jun 26, 2018 | clinicaltrials |
| NCT01331824 | Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma | terminated | Phase 2 | 22 | Matthew GalskyOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01234519 | A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy | terminated | Phase 1 / Phase 2 | 12 | AEterna ZentarisINDUSTRY | 1 | Mar 15, 2018 | clinicaltrials |
| NCT03456401 | Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)(TOKIO) | terminated | Phase 2 | 18 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02122003 | Second Line Sorafenib After Pazopanib in Patients With RCC(SOAP) | terminated | Phase 2 | 16 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT01492192 | RGD-PET-CT in Cancer Angiogenesis | terminated | Phase 2 | 10 | Oxford University Hospitals NHS TrustOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT01784978 | Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer(SUNRISES) | terminated | Phase 2 | 41 | Associació per a la Recerca Oncologica, SpainOTHER | 3 | Oct 2, 2017 | clinicaltrials |
| NCT00003520 | Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer | terminated | Phase 2 | 15 | Burzynski Research InstituteOTHER | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00003452 | Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder | terminated | Phase 2 | 4 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT01622660 | Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02089802 | Optimizing Pazopanib Exposure in RCC Patients(OPERA) | terminated | Phase 2 | 6 | Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.OTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00089778 | Vaccine Treatment of Kidney Cancer | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01042795 | Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy | terminated | Phase 2 | 7 | University of MichiganOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT00934440 | A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma(5-AZ) | terminated | Phase 1 / Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01353222 | DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | terminated | Phase 2 | 142 | DendreonINDUSTRY | 1 | May 25, 2017 | clinicaltrials |
| NCT00651482 | Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) | terminated | Phase 2 | 10 | Sandy SrinivasOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02071641 | Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 5 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT01475266 | Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | terminated | Phase 2 / Phase 3 | 51 | Nippon Kayaku Co., Ltd.INDUSTRY | 2 | Mar 29, 2017 | clinicaltrials |
| NCT00467077 | Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 2 | 21 | California Cancer ConsortiumNETWORK | 1 | Mar 17, 2017 | clinicaltrials |
| NCT01264341 | Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma | terminated | Phase 2 | 39 | Hellenic Cooperative Oncology GroupOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT01441765 | PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | terminated | Phase 2 | 11 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | terminated | Phase 2 | 1 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT00672178 | Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC) | terminated | Phase 1 / Phase 2 | 1 | Duke UniversityOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01712685 | Imaging Studies of Kidney Cancer Using 18F-VM4-037 | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02030574 | Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin | terminated | Phase 2 | 2 | Brown UniversityOTHER | 1 | Aug 24, 2016 | clinicaltrials |
| NCT00022633 | S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract | terminated | Phase 2 | 65 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 11, 2016 | clinicaltrials |
| NCT00318110 | Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 4 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jul 26, 2016 | clinicaltrials |
| NCT01339000 | Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT00831480 | Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal | terminated | Phase 2 | 15 | Linda C. HigginsOTHER | 1 | Mar 21, 2016 | clinicaltrials |
| NCT00440973 | Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer | terminated | Phase 2 | 6 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00522249 | Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | terminated | Phase 1 / Phase 2 | 10 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01916109 | Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | terminated | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT01888042 | Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer(POORTOR) | terminated | Phase 2 | 61 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01762033 | A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma | terminated | Phase 2 | 40 | Lpath, Inc.INDUSTRY | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00480935 | A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma | terminated | Phase 2 | 3 | University Health Network, TorontoOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT01663285 | Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) | terminated | Phase 2 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00913913 | Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients | terminated | Phase 2 | 8 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Dec 1, 2015 | clinicaltrials |
| NCT00714948 | Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 16, 2015 | clinicaltrials |
| NCT00479089 | Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | terminated | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00704938 | Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer | terminated | Phase 2 | 3 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Oct 3, 2018source: clinicaltrials